DiscoveryProbe™ FDA-approved Drug Library: Mechanism-Rich Screening for Drug Repositioning and Target Identification

Executive Summary: The DiscoveryProbe™ FDA-approved Drug Library (L1021) contains 2,320 bioactive compounds that are clinically approved by major regulatory agencies, including the FDA and EMA (APExBIO). Each compound in the library is supplied as a 10 mM solution in DMSO, stable up to 24 months at -80°C. The collection supports high-throughput and high-content screening workflows for drug repositioning, signal pathway regulation, and pharmacological target identification (see full workflow analysis). Benchmarking studies demonstrate successful use of similar FDA-approved drug libraries in GPCR and enzyme inhibitor screens (Ullrich et al. 2023). The kit is compatible with automation platforms and multiple plate formats, facilitating reproducible and scalable biomedical research.

Biological Rationale

FDA-approved bioactive compound libraries provide unique advantages in translational research. Each molecule has been evaluated for safety and efficacy in clinical settings (Ullrich et al. 2023). The DiscoveryProbe™ FDA-approved Drug Library from APExBIO leverages this regulatory validation to accelerate hypothesis testing in both known and novel disease models. The inclusion of drugs with diverse mechanisms—such as receptor agonists, antagonists, enzyme inhibitors, and ion channel modulators—enables systematic exploration of signaling pathways and off-target effects. This approach is integral to drug repositioning, where existing therapies are screened for new indications with reduced development risk (contrast to prior overview article: this section details the safety and mechanistic diversity underpinning the library's design).

Mechanism of Action of DiscoveryProbe™ FDA-approved Drug Library

The DiscoveryProbe™ FDA-approved Drug Library encompasses compounds with well-characterized mechanisms. These include:

• Receptor agonists and antagonists: e.g., befiradol (5-HT1A receptor agonist), metformin (AMPK activator)
• Enzyme inhibitors: e.g., atorvastatin (HMG-CoA reductase inhibitor), doxorubicin (topoisomerase II inhibitor)
• Ion channel modulators: e.g., amiodarone (potassium channel blocker)
• Signal pathway regulators: e.g., kinase inhibitors, GPCR ligands

This mechanism-rich design facilitates the identification of both intended and off-target pharmacological activities. For example, screening FDA-approved drugs enabled the discovery of non-opioid analgesics targeting Gi-coupled serotonin receptors, as shown by Ullrich et al. (2023, DOI).

Evidence & Benchmarks

• Screening of FDA-approved drug libraries identified functionally selective serotonin 5-HT1A receptor agonists effective in pain models, validating the approach for GPCR target identification (Ullrich et al. 2023).
• Over 2,000 FDA-approved drugs are included, with broad regulatory coverage (FDA, EMA, HMA, CFDA, PMDA), ensuring translational relevance (product page).
• Compounds are provided as 10 mM DMSO solutions, stable for 12 months at -20°C and up to 24 months at -80°C, supporting long-term screening campaigns (see scenario-driven integration guide).
• Automated high-content screening platforms are compatible with the library's 96-well and deep-well plate formats (workflow article).
• Drug repositioning screens using this library have uncovered novel indications for cancer, neurodegenerative, and infectious diseases (integrative mechanistic review).

Applications, Limits & Misconceptions

The DiscoveryProbe™ FDA-approved Drug Library is designed for the following applications:

• High-throughput screening (HTS) in cell-based and biochemical assays
• High-content screening (HCS) for phenotypic profiling
• Drug repositioning and target identification workflows
• Mechanistic studies in oncology, neurodegeneration, metabolic and infectious diseases
• Signal pathway regulation and enzyme inhibitor screening

Compared to previous reviews (previous article on repurposing frameworks), this section clarifies the empirical and operational boundaries of the library in screening settings.

Common Pitfalls or Misconceptions

• The DiscoveryProbe™ FDA-approved Drug Library does not include investigational compounds that lack clinical approval.
• Not all compounds are suitable for use in animal models due to species-specific metabolism.
• The library is not a substitute for primary toxicity or ADME/PK screening; further validation is required for hit compounds.
• Compounds are supplied in DMSO; direct use in aqueous assays without dilution may cause precipitation or cytotoxicity.
• The kit does not address regulatory requirements for clinical translation of new indications.

Workflow Integration & Parameters

The DiscoveryProbe™ FDA-approved Drug Library (L1021) is delivered as pre-dissolved 10 mM DMSO solutions, compatible with 96-well microplates, deep well plates, or 2D barcoded screw-top storage tubes. Recommended storage is at -20°C for up to 12 months or -80°C for up to 24 months. Shipping is performed on blue ice for evaluation samples, with room temperature or blue ice options for larger orders (product page). The library is validated for use in automated liquid handlers and plate readers. Prior to screening, thaw plates at room temperature and gently mix to ensure compound homogeneity. For high-throughput screening, dilute compounds into assay-compatible buffers to minimize DMSO concentrations (<2%). For high-content screening, reference control wells and include appropriate positive and negative controls. Each compound is traceable by barcode and plate position, supporting data integrity and reproducibility.

Conclusion & Outlook

The DiscoveryProbe™ FDA-approved Drug Library from APExBIO offers a robust, mechanism-diverse resource for biomedical research. Its regulatory breadth, format flexibility, and compatibility with automation platforms make it a preferred choice for high-throughput and high-content screening. Recent studies demonstrate its value in drug repositioning and target identification, especially in oncology and neurodegeneration. Future applications may include integration with AI-driven hit prediction and multi-omics profiling. For further reading, see the DiscoveryProbe™ FDA-approved Drug Library product page.